A human approach to drug development: Opportunities and limitations

Alternatives to Laboratory Animals

Volumn 38, Issue SUPPL. 1, 2010, Pages 21-25

  Coleman, Robert A ^a  

^a NONE   (United Kingdom)

Author keywords

Drug development; Human tissues; Pharmaceutical industry

Indexed keywords

DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; HUMAN; MASS SPECTROMETRY; NATIONAL HEALTH SERVICE; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW;

EID: 79551696304     PISSN: 02611929     EISSN: None     Source Type: Journal    
DOI: 10.1177/026119291003801s06     Document Type: Review

References (16)

1. Garnier, J.P. (2008). Rebuilding the R&D engine in big pharma. Harvard Business Review 86, 68-70, 72-76, 128.
2. Greaves, P., Williams, A. & Eve, M. (2004). First dose of potential new medicines to humans: How animals help. Nature Reviews Drug Discovery 3, 226-236. (Pubitemid 38379989)
3. Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., Dorato, M., Van Deun, K., Smith, P., Berger, B. & Heller, A. (2000). Concordance of the toxicity of pharmaceuticals in humans and in animals. Regulatory Toxicology & Pharmacology 32, 56-67.
4. Pound, P., Ebrahim, S., Sandercock, P., Bracken, M.B. & Roberts, I. (2004). Where is the evidence that animal research benefits humans? BMJ 328, 514-517.
5. Knight, A. (2008). Systematic reviews of animal experiments demonstrate poor contributions toward human healthcare. Review of Recent Clinical Trials 3, 89-96.
6. Bailey, J. (2005). Non-human primates in medical research and drug development: A critical review. Biogenic Amines 19, 235-255.
7. Suntharalingam, G., Perry, M.R., Ward, S., Brett, S.J., Castello-Cortes, A., Brunner, M.D. & Panoskaltsis, N. (2006). Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. New England Journal of Medicine 355, 1018-1028. (Pubitemid 44343545)
8. Lappin, G. & Garner, R.C. (2003). Big physics, small doses - the use of AMS and PET in human microdosing of development drugs. Nature Reviews Drug Discovery 2, 233-240. (Pubitemid 37361669)
9. Sandhu, P., Vogel, J.S., Rose, M.J., Ubick, E.A., Brunner, J.E., Wallace, M.A., Adelsberger, J.K., Baker, M.P., Henderson, P.T., Pearson, P.G. & Baillie, T.A. (2004). Evaluation of microdosing strategies for studies in preclinical drug development: Demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range. Drug Metabolism & Disposition 32, 1254-1259.
10. Combes, R.D., Berridge, T., Connelly, J., Eve, M.D., Garner, R.C., Toon, S. & Wilcox, P. (2003). Early microdose drug studies in human volunteers can minimise animal testing: Proceedings of a workshop organised by Volunteers in Research and Testing. European Journal of Pharmaceutical Science 19, 1-11. (Pubitemid 36506932)
11. Center for Drug Evaluation and Research (2005). Guidance for Industry, Investigators and Reviewers: Exploratory IND Studies. Draft Guidance. Bethesda, MD, USA: US Department of Health and Human Services Food and Drug Administration. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm078933.pdf (Accessed 28.09.09).
12. Cronin, M., Enoch, S., Hewitt, M., Madden, J., Roberts, D. & Rowe, P. (2007). Computational prediction of toxicity and metabolic transformation. Liverpool, UK: Liverpool John Moores University. Available at: www.ebi.ac.uk/Information/events/therapeutic/doc/M-Cronin.ppt (Accessed at 28.09.09).
13. Jensen, G.E., Niemela, J.R., Wedebye, E.B. & Nikolov, N.G. (2008). QSAR models for reproductive toxicity and endocrine disruption in regulatory use - a preliminary investigation. SAR & QSAR in Environmental Research 19, 631-641.
14. Li, H., Sun, J., Fan, X., Sui, X., Zhang, L., Wang, Y. & He, Z. (2008). Considerations and recent advances in QSAR models for cytochrome P450-mediated drug metabolism prediction. Journal of Computer-aided Molecular Design 22, 843-855.
15. Brightman, F.A., Leahy, D.E., Searle, G.E. & Thomas, S. (2006). Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in human plasma. Drug Metabolism & Disposition 34, 94-101. (Pubitemid 43042650)
16. Gedeck, P. & Lewis, R.A. (2008). Exploiting QSAR models in lead optimization. Current Opinion in Drug Discovery & Development 11, 569-575. (Pubitemid 351950851)